Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point

Haematologica. 2015 Aug;100(8):e328-30. doi: 10.3324/haematol.2014.120790. Epub 2015 Apr 3.

Authors

Affiliations

¹ University of Athens School of Medicine, Greece [email protected].
² Sapienza University of Rome, Italy.
³ Frankston Hospital, Monash University, Victoria, Australia.
⁴ University of Münster, Germany.
⁵ University of Athens School of Medicine, Greece.
⁶ Celgene Corporation, Summit, NJ, USA.
⁷ University of Turin, Italy.

No abstract available

Keywords: MM-015; PFS2; lenalidomide; maintenance; newly diagnosed multiple myeloma (NDMM).

Publication types

Clinical Trial, Phase III
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease-Free Survival
Humans
Maintenance Chemotherapy
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Treatment Outcome

Associated data

ClinicalTrials.gov/NCT00405756